Browse the evidence

Nutrition-sensitive programs that utilize direct food transfers or asset transfers (such as livestock or poultry) yield the largest improvements in micronutrient intake (iron, zinc, vitamin A, animal protein) for children under five, but incur significantly higher costs per child reached compared to programs focused on education, media campaigns, or market access.

For maximum nutritional impact in resource-poor settings, direct provision of food or productive assets (like livestock or seeds) to families with young children is more effective at closing critical nutrient gaps (iron, zinc, vitamin A) than education or cash alone. However, this comes at a significantly higher financial cost. Decision-makers must weigh the higher immediate expense against the greater health benefits for children, recognizing that cheaper education-only programs may not sufficiently improve dietary quality.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce the risk of macroalbuminuria and renal function decline in patients with Type 2 Diabetes.

GLP-1 medications like semaglutide and liraglutide are not just for blood sugar; they also protect your kidneys. Studies show they significantly lower the risk of developing macroalbuminuria, a key marker of kidney damage.

Leptin therapy is effective for weight loss only in patients with leptin deficiency (low circulating levels), not in those with leptin resistance (high levels).

Leptin injections are only effective for people with a specific genetic deficiency causing low leptin levels. For most people with obesity, leptin levels are high, and leptin injections do not work.

BMI is a non-specific composite index of risk that fails to distinguish between body fat and muscle mass, leading to misclassification of health risk in certain populations (e.g., athletes, different ethnicities).

If you are muscular or have a different body type, BMI might not reflect your health accurately. Use other measures like waist circumference or body composition analysis if possible. However, for the general population, BMI remains a useful, albeit imperfect, tool for assessing overall health risk.

An intensive lifestyle intervention (ILI) for weight loss in adults with type 2 diabetes and overweight/obesity is not cost-effective over a 9-year period compared to standard diabetes support and education (DSE), as the high cost of delivering the intervention is not offset by sufficient gains in quality-adjusted life years (QALYs).

For patients with type 2 diabetes, intensive lifestyle changes (like losing 7% of body weight) do improve health markers and may save some medical costs, but the program itself is expensive to run. Over 9 years, the health benefits (QALYs) gained are small and may not justify the high cost of intensive counseling for everyone. However, for individuals who prefer to avoid medication, lifestyle modification remains a valid, effective option for improving blood sugar and blood pressure, even if it is not 'cost-effective' from a system-wide perspective.

Patients with severe obesity and Type 2 Diabetes experience a greater reduction in all-cause mortality from bariatric surgery compared to those with severe obesity alone.

If you have severe obesity and Type 2 Diabetes, bariatric surgery offers an even greater survival benefit than for those with obesity alone. This makes it a particularly strong consideration for managing your health and longevity.

Loss of GIP receptor (GIPR) signaling specifically in GABAergic neurons enhances the body weight loss efficacy of GLP-1 receptor agonists (such as semaglutide or tirzepatide) and dual incretin agonists.

Current obesity medications that target both GLP-1 and GIP receptors (like tirzepatide) work partly by engaging specific brain neurons (GABAergic neurons expressing GIPR). Research suggests that the body's natural GIP signaling in these neurons might actually limit how much weight you can lose with GLP-1 drugs alone. This implies that future treatments might be optimized by either stimulating or blocking GIP signaling in these specific brain cells to maximize weight loss while managing side effects like nausea.

Systemic inhibition of the chromatin modifier LSD1 using GSK-LSD1 or SP2509 reduces body weight, improves insulin sensitivity, and reverses nonalcoholic fatty liver disease (NAFLD) in obese mouse models, independent of reduced food intake.

Targeting the enzyme LSD1 appears to fix the underlying metabolic dysfunction in obesity, not just cause weight loss. It reduces fat tissue inflammation and stops fat from flooding the liver, improving insulin sensitivity directly. This suggests that future drugs targeting LSD1 could treat obesity and its complications like fatty liver and diabetes simultaneously, rather than just suppressing appetite.

Housing mice at thermoneutrality (30°C) rather than standard room temperature (22°C) does not improve the prediction of human drug efficacy for weight loss, as the direction and magnitude of drug effects vary by mechanism regardless of temperature.

This paper is a methodological critique for preclinical researchers, not a direct guide for human behavior. It suggests that while standard mouse housing (22°C) creates thermal stress, simply moving to thermoneutrality (30°C) does not solve the translatability problem for obesity drugs. Researchers should test drugs at both temperatures to understand mechanism-specific responses, as efficacy can flip depending on the thermal environment.

GLP-1 receptor agonists (like semaglutide) and hFGF21 analogs produce similar weight loss efficacy in mice regardless of whether they are housed at standard room temperature (22°C) or thermoneutrality (30°C).

For GLP-1 and hFGF21 drugs, the mouse model's housing temperature is less critical for predicting efficacy magnitude than for other drug classes. These drugs work robustly in both cold-stressed and thermoneutral environments.

GDF15 analogs are significantly more effective at inducing weight loss in mice housed at standard room temperature (22°C) compared to thermoneutrality (30°C), with efficacy dropping by half at higher temperatures.

If developing GDF15-based therapies, preclinical data from cold-housed mice may overestimate efficacy compared to thermoneutral conditions. The drug's effectiveness is halved when mice are not cold-stressed.

Peptide YY (PYY) analogs show greater weight loss efficacy in mice housed at thermoneutrality (30°C) compared to standard room temperature (22°C), contrary to the trend seen with GDF15.

For PYY-based therapies, preclinical data from thermoneutral mice may better reflect potential efficacy than data from cold-stressed mice, where the drug appears largely ineffective.

Semaglutide treatment for type 2 diabetes does not directly cause retinal damage; observed early worsening of diabetic retinopathy is primarily driven by the magnitude and speed of HbA1c reduction rather than the drug itself.

If you have type 2 diabetes and are starting semaglutide, do not avoid it out of fear of blindness. The risk of retinopathy worsening is linked to how fast your blood sugar drops, not the drug itself. To stay safe, your doctor should check your eyes before starting, and may reduce your insulin or sulfonylurea dose to prevent a rapid glucose drop. Regular eye exams are essential.

There is no clinically relevant difference in individual response heterogeneity (variability in body mass change) between low-carbohydrate and low-fat diets.

If you are choosing between a low-carbohydrate and a low-fat diet for weight loss, do not expect one to be inherently more 'unpredictable' or variable in its results than the other. The variability in how much weight people lose is similar for both approaches. Therefore, the choice should be based on preference, adherence, and health markers rather than an expectation of superior or inferior individual response variability.

Infusion of amino acids to maintain near-basal plasma concentrations in overnight-fasted humans induces insulin resistance by decreasing tissue responsiveness to insulin without altering sensitivity, suggesting a postreceptor defect.

If you are receiving intravenous nutrition containing amino acids while your body is producing or receiving high levels of insulin, your body will become less efficient at processing glucose. This is not a failure of your pancreas, but a direct effect of the amino acids on how insulin works at the cellular level (postreceptor). For healthy individuals eating normally, this effect is likely minimal, but for critically ill patients on parenteral nutrition, it is a significant clinical factor.

Duodenal-jejunal bypass liner (DJBL) therapy causes significant depletion of essential fatty acids (linoleic acid, alpha-linolenic acid) and their long-chain polyunsaturated derivatives (arachidonic, eicosapentaenoic, docosahexaenoic acids) in the blood.

If you undergo DJBL (EndoBarrier) therapy, you are at high risk for depleting essential fatty acids (Omega-3 and Omega-6). This device blocks absorption in the upper small intestine. To mitigate this, you must ensure adequate dietary intake of healthy fats (fish, nuts, seeds) or take high-quality fish oil/PUFA supplements, as standard diets may not be enough to overcome the malabsorption. Monitor your levels with your doctor.

Bariatric surgery significantly reduces all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE) compared to medical therapy in patients with severe obesity and Type 2 Diabetes.

For severe obesity and Type 2 Diabetes, bariatric surgery is the most effective treatment for reducing heart disease risk and death. It significantly lowers the risk of heart attack, stroke, and heart failure compared to medical therapy alone. Discuss surgical options with a specialist if lifestyle changes and medications are insufficient.

SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalization in insulin-resistant patients by promoting ketone body production and reducing sympathetic overdrive.

If you have Type 2 Diabetes and heart issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga). They are proven to protect your heart and reduce hospital stays, not just lower blood sugar. The benefit comes from how they change your heart's energy use and stress levels.

GLP-1 receptor agonists reduce major adverse cardiac events and cardiovascular mortality in patients with Type 2 Diabetes, particularly those without pre-existing heart failure.

If you have Type 2 Diabetes, GLP-1 drugs (like Ozempic or Victoza) are highly recommended for heart protection. They significantly lower the risk of heart attacks and death. If you already have heart failure, they still help prevent new cases but may not stop existing failure from worsening as effectively.

SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, resulting in glucosuria, with efficacy dependent on maintaining a filtered glucose load above 80g/day.

SGLT2 inhibitors are effective for lowering blood sugar by helping your kidneys excrete excess glucose, but they only work well if your blood sugar is high enough and your kidneys are functioning adequately. They also offer heart and kidney protection. You must take them as prescribed and maintain good hygiene to minimize infection risks.

Bariatric surgery is a highly effective therapeutic option for individuals with severe obesity (BMI ≥40 or ≥35 with comorbidities) that induces T2DM remission through metabolic changes beyond simple restriction.

If you have a BMI of 40 or higher (or 35+ with diabetes/liver disease), consult a specialist about bariatric surgery. It is a proven, durable treatment that can reverse diabetes through hormonal changes, not just weight loss, but requires lifelong medical monitoring.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve MASH resolution but do not significantly improve liver fibrosis in patients with compensated cirrhosis.

Semaglutide (2.4mg weekly) helps resolve MASH but does not reverse fibrosis in patients with cirrhosis. It is effective for weight loss and glucose control but should not be relied upon to fix advanced scarring alone.

Aggregation of modifiable risk factors (hypertension, overweight/obesity, dyslipidemia, smoking) significantly increases the prevalence of stroke in middle-aged and elderly Chinese patients with type 2 diabetes.

If you have Type 2 Diabetes, managing your blood sugar is not enough to prevent stroke. You must aggressively manage your blood pressure, maintain a healthy weight, control cholesterol, and avoid smoking. The risk of stroke multiplies as you accumulate these risk factors.

Lifestyle interventions (diet and exercise) for diabetes prevention are discursively constructed around the assumption that weight loss is the primary, sufficient, and controllable mechanism for preventing type 2 diabetes, despite evidence that long-term diabetes incidence reduction is not guaranteed and mechanisms are often unspecified.

Do not assume that losing weight will automatically prevent diabetes, nor that your worth is tied to your ability to maintain a strict lifestyle. The science shows that while lifestyle changes help, they are not a guaranteed fix, and the biological mechanisms are complex. Focus on sustainable health behaviors rather than chasing weight loss as a moral imperative or a guaranteed cure.